Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;20(4):361–365. doi: 10.1002/clc.4960200412

Plasma nitrite/nitrate level is inversely correlated with plasma low‐density lipoprotein cholesterol level

Seiya Tanaka 1, Akira Yashiro 1,, Masaharu Ikeda 1, Akio Kuroiwa 1, Yasuhide Nakashima 2, Hiroki Nanri 2
PMCID: PMC6655312  PMID: 9098596

Abstract

Background: Plasma nitrite/nitrate (NOx) is a stable end product of the vasodilator nitric oxide (NO). However, there are few reports about plasma NOx levels in humans.

Hypothesis: The purpose of this study was to assess the availability of plasma NOx for evaluating basal endogenously‐synthesized or endothelium‐derived NO, and to examine whether NOx levels are lowered in patients with coronary artery disease (CAD) or its risk factors.

Methods: Plasma NOx levels were measured using an automated system based on the Griess reaction. NOx levels for a 24‐h period reproducibly became lowest at 6 A.M. in restricted healthy volunteers, and became stable in inpatient volunteers at 6 A.M. within 4 days after admission.

Results: Based on these findings, NOx levels at 6 A.M. in inpatients can be considered as the basal levels. In 40 inpatients suspected of CAD (28 men, 12 women; mean age 60 ± 11 years), the basal levels of NOx were not related to CAD and its risk factors, except for hypercholesterolemia. The NOx level of patients with hypercholesterolemia was significantly lower than that of patients with normal cholesterol (n = 16, 34 ± 16 μmol/l vs. n = 24, 49 ± 23 μmol/l, p < 0.03). Furthermore, the NOx levels correlated negatively with the total cholesterol and low‐density lipoprotein cholesterol levels (r= –0.40, p < 0.01; r = –0.47, p < 0.003, respectively), but not with other lipid fraction levels.

Conclusion: The results suggest that the quantity of basal endothelium‐derived NO synthesis may be decreased in the presence of hypercholesterolemia.

Keywords: plasma nitrite/nitrate, endothelium‐derived nitric oxide, Griess reaction, coronary artery disease, coronary risk factors, hypercholesterolemia, low‐density lipoprotein

Full Text

The Full Text of this article is available as a PDF (543.7 KB).

References

  • 1. Calver A, Collier J, Vallance P: Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin‐dependent diabetes. J Clin Invest 1992; 90: 2548–2554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III: Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95: 1747–1755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide anion is involved in the breakdown of endothelium‐derived vascular relaxing factor. Nature 1986; 320: 454–456. [DOI] [PubMed] [Google Scholar]
  • 4. Wennmalm Å, Benthin G, Edlund A, Jungersten L, Kieler‐Jensen N, Lundin S, Westfelt UN, Petersson AS, Waagstein F: Metabolism and excretion of nitric oxide in humans: An experimental and clinical study. Circ Res 1993; 73: 1121–1127. [DOI] [PubMed] [Google Scholar]
  • 5. Ischiropoulos H, Zhu L, Beckman JS: Peroxynitrite formation from macrophage‐derived nitric oxide. Arch Biochem Biophys 1992; 298: 446–451. [DOI] [PubMed] [Google Scholar]
  • 6. Drexler H, Zeiher AM, Meinzer K, Just H: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L‐arginine. Lancet 1991; 338: 1546–1550. [DOI] [PubMed] [Google Scholar]
  • 7. Flavahan NA: Atherosclerosis or lipoprotein‐induced endothelial dysfunction: Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992; 85: 1927–1938. [DOI] [PubMed] [Google Scholar]
  • 8. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546–2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Kanno K, Hirata Y, Emori T, Ohta K, Eguchi S, Imai T, Marumo F: L‐arginine infusion induces hypotension and diuresis/natriuresis with concomitant increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin Exp Pharmacol Physiol 1992; 19: 619–625. [DOI] [PubMed] [Google Scholar]
  • 10. Tasaki H, Nakashima Y, Nandate H, Yashiro A, Kawashima T, Kuroiwa A: Comparison of serum lipid values in variant angina pectoris and fixed coronary artery disease with normal subjects. Am J Cardiol 1989; 63: 1441–1445. [DOI] [PubMed] [Google Scholar]
  • 11. Mancini G, Carbonara AO, Heremans JF: Immunochemical quantitation of antigens by single radial immunodiffusion. Int J Immunolchem 1965; 2: 235–254. [DOI] [PubMed] [Google Scholar]
  • 12. Takahashi H, Nakanishi T, Nishimura M, Tanaka H, Yoshimura M: Measurement of serum levels of nitrate ions in men and women: Implications of endothelium‐derived relaxing factor in blood pressure regulation and atherosclerosis. J Cardiovasc Pharmacol 1992; 20 (suppl 12): S214–S216. [DOI] [PubMed] [Google Scholar]
  • 13. Winlaw DS, Smythe GA, Keogh AM, Schyvwens CG, Spratt PM, Macdonald PS: Increased nitric oxide production in heart failure. Lancet 1994; 344: 373–374. [DOI] [PubMed] [Google Scholar]
  • 14. Zeballos GA, Bernstein RD, Thompson CI, Forfia PR, Seyedi N, Shen W, Kaminski PM, Wolin MS, Hintze TH: Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation 1995; 91: 2982–2988. [DOI] [PubMed] [Google Scholar]
  • 15. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1991; 6: 3051–3064. [PubMed] [Google Scholar]
  • 16. Wennmalm Å, Benthin G, Edlund A, Kieler‐Jensen N, Lundin S, Petersson AS, Waagstein F: Nitric oxide synthesis and metabolism in man. Ann N Y Acad Sci 1994; 714: 158–164. [DOI] [PubMed] [Google Scholar]
  • 17. Calver A, Collier J, Moncada S, Vallance P: Effect of local intra‐arterial NG‐monomethyl‐L‐arginine in patients with hypertension: The nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10: 1025–1031. [PubMed] [Google Scholar]
  • 18. Yamazaki J, Fujita N, Nagao T: N‐monomethyl‐L‐arginine‐induced pressor response at developmental and established stages in spontaneously hypertensive rats. J Pharmacol Exp Ther 1991; 259: 52–57. [PubMed] [Google Scholar]
  • 19. Kelm M, Feelisch M, Krebber T, Motz W, Strauer BE: The role of nitric oxide in the regulation of coronary vascular resistance in arterial hypertension: Comparison of normotensive and spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 20: 183–186. [DOI] [PubMed] [Google Scholar]
  • 20. Liao JK, Shin WS, Lee WY, Clark SL: Oxidized low‐density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319–324. [DOI] [PubMed] [Google Scholar]
  • 21. Chen LY, Mehta P, Mehta JL: Oxidized LDL decreases L‐arginine uptake and nitric oxide synthase protein expression in human platelets: Relevance of the effect of oxidized LDL on platelet function. Circulation 1996; 93: 1740–1746. [DOI] [PubMed] [Google Scholar]
  • 22. Böger RH, Bode‐Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, Frölich JC: Supplementation of hypercholesterolaemic rabbits with L‐arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995; 117: 273–284. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES